AAPGAscentage Pharma Group Inc.Signing up patients
APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Neuroblastoma · Solid Tumor
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 100 (planned)
- Started
- Feb 28, 2023
- Main results expected
- Jun 1, 2027
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Limiting Toxicity (Phase I)
Measured over: Up to 21 days
Treatment-Emergent Adverse Events per NCI-CTCAE version 5.0
Measured over: Up to 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05701306 · record last updated 2026-08-21 · checked 2026-11-09 15:47 UTC